Form 4: Illumina SVP, Chief Commercial Officer Everett Cunningham Reports Changes in Beneficial Ownership

Everett Cunningham, SVP, Chief Commercial Officer of Illumina, reports acquisition of restricted stock units and performance shares, along with holdings in various IRA and trust accounts.

Summary

• Everett Cunningham, SVP, Chief Commercial Officer of Illumina, filed a Form 4 detailing changes in beneficial ownership.
• On July 5, 2024, Cunningham acquired 36,860 shares of common stock through a grant of restricted stock units, vesting over four years.
• He also acquired 18,430 performance shares tied to Illumina's three-year average operating margin for fiscal years 2024-2026, vesting on January 3, 2027.
• An additional 18,430 performance shares were acquired, linked to Illumina's relative total shareholder return for the fiscal year ending January 3, 2027, also vesting on January 3, 2027.
• Cunningham also reports holdings of 70 shares of common stock as a beneficiary of an IRA, 757 shares in an IRA, 3,151 shares in a revocable trust, and 672 shares in a spouse's IRA.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing indicating standard executive compensation practices. The sentiment is neutral to slightly positive as it reflects alignment of executive interests with company performance.

Positives

• The grant of restricted stock units and performance shares aligns Cunningham's interests with the long-term success of Illumina.
• The vesting conditions based on operating margin and shareholder return incentivize performance and value creation.

Risks

• The actual number of performance shares issued depends on Illumina's performance against pre-defined objectives, which may not be met.
• The vesting of restricted stock units is contingent on Cunningham's continued service as a provider.

Future Outlook

The number of performance shares ultimately received by Cunningham will depend on Illumina's financial performance and shareholder return over the next few years.

Industry Context

This filing is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies like Illumina. It reflects the company's approach to incentivizing its executives through equity-based awards.

Comparison to Industry Standards

• Equity compensation is a standard practice among publicly traded companies, particularly in the technology and biotechnology sectors.
• Companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies also utilize restricted stock units and performance-based equity awards to align executive compensation with company performance.
• The vesting schedules and performance metrics used by Illumina are generally consistent with industry norms.

Stakeholder Impact

• The equity grants could positively impact shareholders if they incentivize management to improve company performance.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates